Mei Han

Mei is currently a Principal Scientist at Merck, DMPK-PDMB, working on new technology implementation and novel workflow development for biotransformation analysis of next-gen biologics and targeted therapies and also serve as bioanalytical lead for a couple of projects. Prior to joining Merck, Mei was a Principal Scientist in PKDM department at Amgen South San Francisco, she led the large molecule biotransformation team within PKDM and served as a PKDM project team representative in project team for multiple projects. Mei has 20+ years’ of biopharma experience in drug discovery and development specialized in analytical sciences, biologics optimization, pharmacokinetics and drug metabolism. As a subject matter expert of protein therapeutics purification and characterization, in vitro (pre-dose) and in vivo (post-dose), her expertise ranging from chromatographic, electrophoresis and mass spectrometry analytical method development, inter- and intra- departmental method transfer, method qualification per ICH guidelines and experience with regulatory filings. She also served as a CE Pharm Committee member and Associate Director for CASSS previously.